88 related articles for article (PubMed ID: 2513287)
21. Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin.
Brune S; Tebbe U; Schmidt T; Benn HP; Seiler KU; Kreuzer H
Clin Physiol Biochem; 1990; 8 Suppl 3():81-4. PubMed ID: 2132177
[TBL] [Abstract][Full Text] [Related]
22. Thrombolytic therapy: a review of the literature on streptokinase and tissue plasminogen activator with implications for practice.
Brewer-Senerchia C
Crit Care Nurs Clin North Am; 1989 Jun; 1(2):359-71. PubMed ID: 2510771
[TBL] [Abstract][Full Text] [Related]
23. [Tissue-type plasminogen activator (t-PA): comments on results of the GISSI-2 study].
Turazza FM
Medicina (Firenze); 1990; 10(2):193-4. PubMed ID: 2125681
[TBL] [Abstract][Full Text] [Related]
24. Effects on chest pain of early thrombolytic treatment in suspected acute myocardial infarction: results from the TEAHAT Study.
Risenfors M; Hartford M; Dellborg M; Edvardsson N; Emanuelsson H; Karlson BW; Sandstedt B; Herlitz J
J Intern Med Suppl; 1991; 734():27-34. PubMed ID: 1900009
[TBL] [Abstract][Full Text] [Related]
25. Tissue plasminogen activator administration and nursing considerations.
Greco A
J Intraven Nurs; 1989; 12(1):20-4. PubMed ID: 2494313
[TBL] [Abstract][Full Text] [Related]
26. [Elements of choice of thrombolytic agents in myocardial infarction].
Samama M; Brochet E; Valère PE
Arch Mal Coeur Vaiss; 1992 May; 85(5 Suppl):721-7. PubMed ID: 1530414
[TBL] [Abstract][Full Text] [Related]
27. [Use of fibrinolytics in the treatment of acute myocardial infarction in Denmark. A questionnaire study].
Nielsen JD; Stoltenberg M; Siemsen M; Juul A; Pedersen F; Madsen JK
Ugeskr Laeger; 1990 Aug; 152(33):2368-70. PubMed ID: 2120830
[TBL] [Abstract][Full Text] [Related]
28. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
[TBL] [Abstract][Full Text] [Related]
29. Role of the clinical laboratory in monitoring fibrinolytic therapy of acute myocardial infarction.
Bovill E; Triplett D; Stump D
Hematol Pathol; 1990; 4(2):61-6. PubMed ID: 2115512
[TBL] [Abstract][Full Text] [Related]
30. Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction.
Massel D; Gill JB; Cairns JA
Can J Cardiol; 1991 Sep; 7(7):298-302. PubMed ID: 1933636
[TBL] [Abstract][Full Text] [Related]
31. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of recombinant tissue plasminogen activator infusion in acute myocardial infarction.
Wang SP; Liu CP; Charng MJ; Chou CY; Tsai JH; Pan JP; Shyong WC; Chan WL; Kong CW; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 1989 Apr; 43(4):223-8. PubMed ID: 2509051
[TBL] [Abstract][Full Text] [Related]
33. Thrombolytic therapy: a case study.
Moseley MJ
Crit Care Nurse; 1992 Mar; 12(3):62-8. PubMed ID: 1559384
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Rapold HJ; Kuemmerli H; Weiss M; Baur H; Haeberli A
Circulation; 1989 May; 79(5):980-9. PubMed ID: 2496939
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Sloan MA; Price TR; Petito CK; Randall AM; Solomon RE; Terrin ML; Gore J; Collen D; Kleiman N; Feit F
Neurology; 1995 Apr; 45(4):649-58. PubMed ID: 7723950
[TBL] [Abstract][Full Text] [Related]
36. Early reperfusion assessment and repeated thrombolysis in acute myocardial infarction estimated by repeated standard electrocardiography. A randomised, double-blind, placebo-controlled pilot study.
Gill S; Haastrup B; Haghfelt T; Dellborg M; Clemmensen PM
Cardiology; 2000; 94(1):58-65. PubMed ID: 11111146
[TBL] [Abstract][Full Text] [Related]
37. [A successful lytic treatment of a perioperative pulmonary embolism necessitating resuscitation using recombinant tissue-type plasminogen activator].
Hopf HB; Grote B; Becker H; Breulmann M
Anaesthesist; 1990 Jan; 39(1):50-2. PubMed ID: 2106276
[TBL] [Abstract][Full Text] [Related]
38. Splenic hemorrhage: a complication of tissue plasminogen activator treatment.
Cheung PK; Arnold JM; McLarty TD
Can J Cardiol; 1990 Jun; 6(5):183-5. PubMed ID: 2116935
[TBL] [Abstract][Full Text] [Related]
39. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction.
Nicolini FA; Ferrini D; Ottani F; Galvani M; Ronchi A; Behrens PH; Rusticali F; Mehta JL
Am J Cardiol; 1994 Oct; 74(7):662-6. PubMed ID: 7942523
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a two-hour infusion of 150-mg tissue plasminogen activator in acute myocardial infarction.
Lew AS; Cercek B; Lewis BS; Hod H; Shah PK; Ganz W
Am J Cardiol; 1987 Dec; 60(16):1225-9. PubMed ID: 3120567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
